Literature DB >> 30375564

The Turkish Version of Multidimensional Assessment of Fatigue and Fatigue Severity Scale is Reproducible and Correlated With Other Outcome Measures in Patients With Systemic Sclerosis.

Kevser Gök1, Gizem Cengiz1, Kemal Erol1, Salih Özgöçmen1.   

Abstract

OBJECTIVES: This study aims to evaluate the reproducibility of Turkish versions of multidimensional assessment of fatigue (MAF) and fatigue severity scales (FSS) and the relationship between health related quality of life, disability, and psychological status in patients with systemic sclerosis (SSc). PATIENTS AND METHODS: A total of 21 female patients (mean age 47.14±10.39 years; range 18 to 75 years) who met 2013 American College of Rheumatology/European League Against Rheumatism criteria for SSc were evaluated for severity of organ involvement and symptoms. Turkish version of MAF, FSS, and visual analog scale of fatigue were assessed at baseline and after two to three weeks. Level of dyspnea was noted and disability, functional limitation, and quality of life were assessed by health assessment questionnaire, 6-minute walking distance, and short-form 36, respectively.
RESULTS: Ten patients had diffuse and 11 had limited SSc. MAF subscales and FSS had significant correlations with short-form 36-vitality subscale and 6-minute walking distance. Intraclass correlation coefficients for FSS and visual analog scale of fatigue were 0.824 (95% confidence interval, 0.566- 0.929) and 0.932 (95% confidence interval, 0.832-0.972), respectively. The intraclass correlation coefficients for MAF subscales changed between 0.916 and 0.968, except for MAF-timing (intraclass correlation coefficient, 0.404).
CONCLUSION: Our results revealed that FSS and MAF subscales had high reproducibility and correlated well with quality of life and disability scales which, to some extent, may suggest convergent validity of MAF subscales and FSS in SSc. The incompatible nature and four-choice answering in two items of MAF-timing may be the underlying reason for trivial relationship with other parameters. The Turkish version of MAF and FSS may be used to assess fatigue in patients with SSc.

Entities:  

Keywords:  Fatigue; Turkish version; scale; systemic sclerosis

Year:  2016        PMID: 30375564      PMCID: PMC6190971          DOI: 10.5606/ArchRheumatol.2016.5909

Source DB:  PubMed          Journal:  Arch Rheumatol        ISSN: 2148-5046            Impact factor:   1.472


  17 in total

1.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

Authors:  E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

2.  2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.

Authors:  Frank van den Hoogen; Dinesh Khanna; Jaap Fransen; Sindhu R Johnson; Murray Baron; Alan Tyndall; Marco Matucci-Cerinic; Raymond P Naden; Thomas A Medsger; Patricia E Carreira; Gabriela Riemekasten; Philip J Clements; Christopher P Denton; Oliver Distler; Yannick Allanore; Daniel E Furst; Armando Gabrielli; Maureen D Mayes; Jacob M van Laar; James R Seibold; Laszlo Czirjak; Virginia D Steen; Murat Inanc; Otylia Kowal-Bielecka; Ulf Müller-Ladner; Gabriele Valentini; Douglas J Veale; Madelon C Vonk; Ulrich A Walker; Lorinda Chung; David H Collier; Mary Ellen Csuka; Barri J Fessler; Serena Guiducci; Ariane Herrick; Vivien M Hsu; Sergio Jimenez; Bashar Kahaleh; Peter A Merkel; Stanislav Sierakowski; Richard M Silver; Robert W Simms; John Varga; Janet E Pope
Journal:  Arthritis Rheum       Date:  2013-10-03

3.  The Swedish version of the Multidimensional Assessment of Fatigue (MAF) in systemic sclerosis: reproducibility and correlations to other fatigue instruments.

Authors:  G Sandqvist; B Archenholtz; A Scheja; R Hesselstrand
Journal:  Scand J Rheumatol       Date:  2011-09-15       Impact factor: 3.641

4.  Validation of the Turkish version of the fatigue severity scale in patients with fibromyalgia.

Authors:  Asli Gencay-Can; Serdar Suleyman Can
Journal:  Rheumatol Int       Date:  2010-07-24       Impact factor: 2.631

5.  Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease.

Authors:  J C Bestall; E A Paul; R Garrod; R Garnham; P W Jones; J A Wedzicha
Journal:  Thorax       Date:  1999-07       Impact factor: 9.139

6.  The validity and reliability of the Fatigue Severity Scale in Turkish multiple sclerosis patients.

Authors:  Kadriye Armutlu; Nilufer Cetisli Korkmaz; Ilke Keser; Vildan Sumbuloglu; Derya Irem Akbiyik; Zafer Guney; Rana Karabudak
Journal:  Int J Rehabil Res       Date:  2007-03       Impact factor: 1.479

Review 7.  Quality of life in systemic sclerosis.

Authors:  Cristiana Almeida; Isabel Almeida; Carlos Vasconcelos
Journal:  Autoimmun Rev       Date:  2015-07-23       Impact factor: 9.754

8.  A validity and reliability study of the Turkish Multidimensional Assessment of Fatigue (MAF) scale in chronic musculoskeletal physical therapy patients.

Authors:  Yücel Yildirim; Gülbin Ergin
Journal:  J Back Musculoskelet Rehabil       Date:  2013       Impact factor: 1.398

Review 9.  Systemic sclerosis: from pathogenesis to targeted therapy.

Authors:  Christopher P Denton
Journal:  Clin Exp Rheumatol       Date:  2015-10-12       Impact factor: 4.473

10.  Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis.

Authors:  P Clements; P Lachenbruch; J Siebold; B White; S Weiner; R Martin; A Weinstein; M Weisman; M Mayes; D Collier
Journal:  J Rheumatol       Date:  1995-07       Impact factor: 4.666

View more
  2 in total

1.  Fatigue, anxiety and depression in patients with prediabetes: a controlled cross-sectional study.

Authors:  Ulaş Serkan Topaloğlu; Kemal Erol
Journal:  Diabetol Int       Date:  2022-04-20

2.  Comparison of Level of Fatigue and Disease Correlates in Patients With Rheumatoid Arthritis and Systemic Sclerosis.

Authors:  Kevser Gök; Kemal Erol; Gizem Cengiz; Salih Özgöçmen
Journal:  Arch Rheumatol       Date:  2018-01-15       Impact factor: 1.472

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.